Navigation Links
High-intensity chemotherapy does not improve survival in small cell lung cancer
Date:4/8/2008

Small cell lung cancer (SCLC) patients treated with high-dose chemotherapy did not have better survival rates than those treated with standard doses, according to a randomized controlled trial published online April 8 in the Journal of the National Cancer Institute.

SCLC accounts for nearly 13 percent of lung cancer cases in the United States. Although many patients with SCLC initially respond to chemotherapy, most suffer disease recurrence relatively quickly. Laboratory data suggest that increasing the dose of chemotherapy agents kills SCLC cells that were resistant to standard doses, and thus might improve patient survival.

To test this possibility, Serge Leyvraz, M.D., of the University Hospital in Lausanne, Switzerland, and colleagues enrolled 140 patients with SCLC in a randomized trial that compared high-dose and standard-dose chemotherapy. Both groups were treated with the same chemotherapy agents, ifosfamide, carboplatin, and etoposide (ICE).

The 3-year survival rates in the two arms were similar, with 18 percent of patients in the high-dose arm and 19 percent of patients in the standard-dose arm still alive. Additionally, a similar fraction of patients in both arms showed tumor shrinkage in response to therapy—78 percent in the high-dose arm and 68 percent in the standard-dose arm, which was not a statistically significant difference.

"The approach explored in the present trial succeeded in raising the peak dose, total dose, and dose intensity of ICE by threefold but has clearly been ineffective and highly toxic," the authors write. "As a result, this strategy should be abandoned."

In an accompanying editorial, Paul A. Bunn Jr., M.D., agrees with that assessment and emphasizes that other avenues of therapy should now be explored. "The declining incidence of SCLC and the lack of progress seem to have dampened the enthusiasm of funding agencies and industry for exploring novel therapies. This is indeed unfortunate because SCLC remains a common cancer in both the developed and developing world," Bunn writes.


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. Medicare modernization act did not change chemotherapy as feared
8. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
9. Cancer conflict with chemotherapy treatment
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... ... 2017 , ... The Military Officers Association of America (MOAA) announced its support ... retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff director ... with the issues and challenges veterans face with the VA. Following a 30-year career ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South ... selected 21 leaders from government, business and civil society in 11 countries across the ... this fall, engaging in a transformative exchange of knowledge and ideas with the leading ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
Breaking Medicine Technology: